Researcher basic information

• Ph.D., Hokkaido University, Mar. 2015
• M.D., Sapporo Medical University, Mar. 2007

• https://researchmap.jp/toshimatsukawa?lang=en

• https://jglobal.jst.go.jp/detail?JGLOBAL_ID=202201005829701718
• https://orcid.org/0000-0003-2371-3778

• https://orcid.org/0000-0003-2371-3778

• 202201005829701718

• HIV/AIDS
• 悪性リンパ腫
• 血液内科
• 白血病

• Life Science, Hematology and medical oncology

• Bachelor's degree program, Departments of Medicine, School of Medicine
• Master's degree program, Graduate School of Medicine
• Doctoral (PhD) degree program, Graduate School of Medicine

Research activity information

• 2021, 米国血液学会, Abstract Achievement Award
• 2021, 米国国立衛生研究所, The Fellows Award for Research Excellence (FARE) Travel Award
• 2019, 上原記念生命科学振興財団, 海外留学助成リサーチフェローシップ
• 2018, 内藤記念科学振興財団, 海外研究留学助成金
• 2015, 北海道大学大学院医学研究科 優秀論文賞
• 2015, 日本免疫学会, Tadamitsu Kishimoto International Travel Award
• 2015, 米国免疫学会, Trainee Poster Award
• 2014, 日本学術振興会特別研究員（DC2）

• Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes
  Toshihiro Matsukawa; Shota Yoshida; Masahiro Onozawa; Fumiaki Fujii; Jun Nagai; Tomoki Takahashi; Shuichi Ota; Junichi Hashiguchi; Akio Mori; Takuto Miyagishima; Makoto Ibata; Yasutaka Kakinoki; Tatsuo Oyake; Satoshi Yamamoto; Toshiaki Hayashi; Kentaro Wakasa; Tomoyuki Saga; Tetsuya Igarashi; Satoshi Iyama; Yutaka Tsutsumi; Katsuya Fujimoto; Masaaki Adachi; Masahiro Yoshida; Daigo Hashimoto; Takanori Teshima
  Hematology, 31 Dec. 2026, [Peer-reviewed], [Lead author]
  Scientific journal
• Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan.
  Minoru Kanaya; Yuji Mukai; Goichi Yoshimoto; Mirei Kobayashi; Sayaka Kajikawa; Toma Suzuki; Naoki Miyashita; Shinpei Harada; Takashi Ishio; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Masanobu Morioka; Akio Mori; Toshihiro Matsukawa; Masahiro Onozawa; Mitsuru Moriyama; SungGi Chi; Kosuke Doki; Takanori Teshima; Yosuke Minami; Masato Homma; Takeshi Kondo
  Blood neoplasia, 3, 3, 100234, 100234, Aug. 2026, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Venetoclax (VEN) combined with azacitidine (AZA) or low-dose cytarabine (LDAC) has significantly improved outcomes for older patients with acute myeloid leukemia (AML). However, severe cytopenia often leads to treatment interruptions. Previous literature has reported that Asian patients tend to have higher plasma VEN concentrations and are more prone to severe neutropenia. We hypothesized that VEN pharmacokinetics (PK) influence these adverse events in the Japanese population. In a prospective observational study (UMIN000047371) involving 76 patients, we monitored VEN PK (trough, maximum plasma concentration, and area under the plasma concentration-time curve from 0 to 12 hours [AUC0-12]). Our analysis of an 81-sample PK data set revealed that samples taken 6 hours after VEN dose offered the best correlation to AUC0-12 (r = 0.945). Importantly, in patients who achieved composite complete remission, a positive correlation was found between the duration of grade 3 neutropenia and VEN AUC0-12 (r = 0.338; P = .028). We further investigated potential factors influencing VEN PK and neutropenia, specifically considering tumor burden and renal function. Samples from patients with pretreatment white blood cell (WBC) counts of <3000/μL and an estimated glomerular filtration rate (eGFR) of <60 mL/min exhibited significantly higher VEN AUC0-12 levels (P = .037) than other groups. These patients also demonstrated a significantly more extended period of grade 3 neutropenia (P = .037). These results suggest that VEN PK could be crucial for predicting neutrophil recovery after VEN-containing regimens in AML. Specifically, patients with low pretreatment WBC counts and low eGFR may represent a risk factor for higher VEN concentrations and, consequently, prolonged neutropenia.
• Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.
  Yu Yagi; Yusuke Kanemasa; Toshiki Terao; Motohiro Kato; Tomoyasu Jo; Tatsu Shimoyama; Toshio Kitawaki; Ryo Hanajiri; Noriko Doki; Satoshi Yoshihara; Nobuharu Fujii; Noriko Iwaki; Go Yamamoto; Masatoshi Sakurai; Toshihiro Matsukawa; Emiko Sakaida; Yasuhiro Nakashima; Akiyo Yoshida; Yoshihiro Umezawa; Haryoon Kim; Keisuke Kataoka; Hideki Goto; Yoshiko Atsuta; Koji Kato
  Blood advances, 10, 13, 4427, 4438, 14 Jul. 2026, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.
• A multicenter real-world study of clinical outcomes in octogenarians and older patients with acute myeloid leukemia.
  Toshihiro Matsukawa; Jun Nagai; Minoru Kanaya; Junichi Hashiguchi; Shuichi Ota; Tomoyuki Saga; Makoto Ibata; Takuto Miyagishima; Yasutaka Kakinoki; Satoshi Yamamoto; Kentaro Wakasa; Toshiaki Hayashi; Katsuya Fujimoto; Tomoki Takahashi; Fumiaki Fujii; Masahiro Onozawa; Daigo Hashimoto; Takanori Teshima
  Leukemia research, 168, 108269, 108269, 26 Jun. 2026, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, BACKGROUND: Acute myeloid leukemia (AML) predominantly affects older adults; however, patients aged ≥ 80 years remain underrepresented in clinical trials, and their real-world outcomes and prognostic determinants remain unclear. METHODS: This multicenter retrospective cohort study (SNOWFALL: Study of Northern Outcomes With Frailty and Acute Leukemia in Late Life) used the Hokkaido Leukemia Net registry. Consecutive patients aged ≥ 80 years with newly diagnosed AML between 2020 and 2024 were analyzed. Clinical characteristics, treatments, overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and prognostic performance of a clinical-biological risk score were evaluated. RESULTS: A total of 154 patients (median age, 84 years) were evaluated, with a median OS of 237 days. Although unadjusted OS did not differ significantly between patients aged 80-84 years and those aged ≥ 85 years, multivariable analysis identified age ≥ 85 years, Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2, and high clinical-biological risk as independent adverse factors for OS. Increasing age and ECOG PS ≥ 2 were independently associated with 30-day mortality (odds ratios per year, 1.16 and 3.35, respectively). RFS and CIR did not differ significantly by age group. Non-relapse mortality analysis showed no significant trend toward higher NRM in patients aged ≥ 85 years and those with ECOG PS ≥ 2. CONCLUSIONS: In this real-world cohort, patients aged ≥ 80 years demonstrated poor outcomes. Prognosis may be more strongly associated with clinical vulnerability than with chronological age or relapse-related outcomes, highlighting the limitations of age-based risk models and the need for refined, clinically informed risk stratification and treatment strategies tailored to very elderly patients with AML.
• Perioperative pharmacokinetics of lenacapavir during massive hemorrhage in a patient with hemophilia a undergoing liver transplantation
  Tomoyuki Endo; Yuki Tazawa; Toshihiro Matsukawa; Yuta Hasegawa; Ryoichi Goto; Tsuyoshi Shimamura; Hajime Matsushima; Takanobu Hara; Akihiko Soyama; Takanori Teshima; Susumu Eguchi
  Journal of Infection and Chemotherapy, 32, 6, 102980, 102980, Jun. 2026, [International Magazine]
  English, Scientific journal, Lenacapavir (LEN) is a long-acting HIV-1 capsid inhibitor administered subcutaneously every six months; however, its pharmacokinetic behavior during massive hemorrhage is unknown. We report a man in his 60s with multidrug-resistant HIV-1 infection and severe hemophilia A who underwent living-donor liver transplantation for HCV-related hepatocellular carcinoma. After a 2-week oral loading phase, LEN (927 mg) was administered four weeks before surgery. Liver transplantation was performed with intraoperative blood loss of 7046 g, approximately 1.5 times the estimated circulating blood volume. Despite this massive hemorrhagic stress, plasma LEN concentrations were 59.9 ng/mL on the day of surgery and 57.3 ng/mL on postoperative day 1, showing minimal change without additional dosing. Twenty-four weeks after the first injection, immediately before the second scheduled dose, plasma LEN concentration remained adequate at 80.8 ng/mL. HIV-1 RNA remained suppressed below 20 copies/mL throughout the clinical course. To our knowledge, this is the first report describing perioperative LEN pharmacokinetics during massive blood loss. These findings indicate that LEN exposure may remain stable despite substantial intravascular volume depletion, supporting the pharmacokinetic robustness of long-acting antiretroviral therapy in major surgical settings.
• Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study.
  Shota Yokoyama; Masahiro Onozawa; Hiroyuki Kimura; Takahide Ara; Jun Nagai; Shota Yoshida; Naoki Miyashita; Toshihiro Matsukawa; Hideki Goto; Shinsuke Hirabayashi; Minoru Kanaya; Akio Mori; Daisuke Hidaka; Junichi Hashiguchi; Kentaro Wakasa; Makoto Ibata; Yukari Takeda; Takuto Miyagishima; Satoshi Yamamoto; Katsuya Fujimoto; Toma Suzuki; Tomoyuki Saga; Hajime Sakai; Yasutaka Kakinoki; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
  International journal of hematology, 22 Apr. 2026, [Domestic magazines]
  English, Scientific journal, Chronic myelogenous leukemia that carries the BCR::ABL1 fusion gene without cytogenetically detectable Philadelphia (Ph) chromosomes is termed masked Ph. However, the prevalence and clinical relevance of masked Ph in acute lymphoblastic leukemia (ALL) remain unclear. Using the Hokkaido Leukemia Net real-world multicenter cohort, we analyzed 160 B-cell ALL patients diagnosed between 2017 and 2024 with available cytogenetic and molecular data. Among 92 BCR::ABL1-positive cases, 19 (20.7%) lacked a cytogenetically visible Ph chromosome and were classified as masked-Ph ALL. Compared with Ph + ALL, masked-Ph patients were older and had lower white blood cell counts and bone marrow blast percentages at diagnosis. Most BCR::ABL1-positive patients received tyrosine kinase inhibitors (TKIs) during induction, resulting in comparable complete remission rates and similar overall survival between masked-Ph and Ph + ALL; both groups showed superior outcomes compared with BCR::ABL1-negative ALL. The number of metaphases analyzed by G-banding was significantly lower in masked-Ph ALL, suggesting underdetection by conventional cytogenetics. One case exhibited an atypical FISH pattern consistent with a cryptic microinsertion. These findings indicate that masked-Ph ALL is relatively common and may be overlooked without molecular testing, underscoring the importance of incorporating RT-PCR and FISH at diagnosis.
• Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review.
  Shingo Nojima; Toru Miyajima; Reiki Ogasawara; Shota Yoshida; Hiroyuki Kimura; Rintaro Nozu; Fuka Horikita; Takahide Ara; Toshihiro Matsukawa; Souichi Shiratori; Masahiro Onozawa; Masao Nakagawa; Takanori Teshima
  Leukemia & lymphoma, 1, 4, 08 Apr. 2026, [International Magazine]
  English, Scientific journal
• Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study
  Souichi Shiratori; Keito Suto; Yuta Hasegawa; Takahide Ara; Toshihiro Matsukawa; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daisuke Hidaka; Reiki Ogasawara; Kohei Okada; Junichi Sugita; Yasutaka Kakinoki; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
  Transplantation and Cellular Therapy, Mar. 2026
  Scientific journal
• Platelet Recovery and Its Impact on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Nationwide Retrospective Study
  Naoki Kurita; Kazushi Maruo; Fumihiko Kimura; Yachiyo Kuwatsuka; Toshihiro Matsukawa; Takaaki Konuma; Shinichi Kobayashi; Mamiko Sakata‐Yanagimoto; Noriko Doki; Masatsugu Tanaka; Naoyuki Uchida; Tetsuya Nishida; Masashi Sawa; Yuta Hasegawa; Hirohisa Nakamae; Shuichi Ota; Makoto Onizuka; Takahiro Fukuda; Nobuhiro Hiramoto; Toshiro Kawakita; Noboru Asada; Fumihiko Ishimaru; Junya Kanda; Ken Tabuchi; Yoshiko Atsuta; Hideki Nakasone
  American Journal of Hematology, 101, 1, 193, 197, Wiley, 29 Oct. 2025, [Peer-reviewed]
  Scientific journal
• Dermoscopic Rosettes in Cutaneous Chronic Graft‐Versus‐Host Disease
  Asuka Oikawa; Ken Natsuga; Mika Watanabe; Toshihiro Matsukawa; Hideyuki Ujiie
  The Journal of Dermatology, Oct. 2025
  Scientific journal
• Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks
  Shota Yoshida; Masahiro Onozawa; Shota Yokoyama; Toshihiro Matsukawa; Hideki Goto; Shinsuke Hirabayashi; Takeshi Kondo; Daigo Hashimoto; Yasuhito Onodera; Takanori Teshima
  Experimental Hematology, Sep. 2025
  Scientific journal
• Early cardiotoxicity in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-haploidentical hematopoietic stem cell transplantation
  Toshihiro Matsukawa; Junichi Sugita; Daigo Hashimoto; Masayuki Aiba; Kohei Okada; Takanori Teshima
  International Journal of Hematology, Aug. 2025
  Scientific journal
• Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.
  Minoru Kanaya; Masahiro Onozawa; Toshihiro Matsukawa; Naoki Miyashita; Fumiaki Fujii; Shota Yoshida; Jun Nagai; Masayuki Aiba; Daisuke Hidaka; Junichi Hashiguchi; Hajime Senjo; Tetsuyuki Igarashi; Masahiro Chiba; Satoshi Yamamoto; Taku Shimizu; Takashi Ishio; Shota Yokoyama; Ko Ebata; Satoshi Iyama; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
  Blood cancer journal, 15, 1, 118, 118, 03 Jul. 2025, [International Magazine]
  English
• CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway.
  Naoki Miyashita; Masahiro Onozawa; Kohei Kasahara; Toshihiro Matsukawa; Yasuhito Onodera; Kohjin Suzuki; Tomoiku Takaku; Takanori Teshima; Takeshi Kondo
  Cancer science, 04 Feb. 2025, [International Magazine]
  English, Scientific journal, In this study, the mechanisms of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML) were investigated focusing additional sex combs-like 1 (ASXL1) gene mutations and their downstream effects. While TKIs have improved the prognosis of CML, some patients have shown resistant to therapy. Cases with mutations in epigenome-related genes such as ASXL1 are known to have a poor prognosis, but the underlying mechanisms of the poor prognosis are unclear. We showed that mutated ASXL1 reduces TKI sensitivity in CML cell lines, and RNA microarray analysis revealed that arachidonate 5-lipoxygenase (ALOX5) is a significantly upregulated gene under the conditional expression of mutated ASXL1. Enforced ALOX5 expression induced TKI resistance, while ALOX5 knockout increased TKI sensitivity. ALOX5 downstream signal inhibition by LY293111, a leukotriene B4 receptor (BLTR) antagonist, suppressed AKT phosphorylation and enhanced TKI sensitivity. This study revealed that TKI resistance in CML with ASXL1 mutation was induced via ALOX5 overexpression. ASXL1 mutations may confer a clonal advantage through activation of the AKT pathway following ALOX5 overexpression. While combined use of LY293111 with TKIs and asciminib showed synergistic effects against CML cells, the ALOX5-BLTR signaling pathway is novel therapeutic target for CML patients with mutated ASXL1.
• Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
  Naoki Kurita; Kazushi Maruo; Fumihiko Kimura; Yachiyo Kuwatsuka; Toshihiro Matsukawa; Takaaki Konuma; Shinichi Kobayashi; Mamiko Sakata-Yanagimoto; Noriko Doki; Masatsugu Tanaka; Naoyuki Uchida; Tetsuya Nishida; Masashi Sawa; Yuta Hasegawa; Hirohisa Nakamae; Shuichi Ota; Makoto Onizuka; Takahiro Fukuda; Fumihiko Ishimaru; Ken Tabuchi; Yoshiko Atsuta; Junya Kanda; Hideki Nakasone
  Blood, 144, Supplement 1, 2121, 2121, American Society of Hematology, 05 Nov. 2024
  Scientific journal, Background: Thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HCT), which can lead to increased mortality and impaired quality of life with prolonged transfusion dependency and high risk of bleeding. However, it is not clear how many patients survive without sufficient platelet recovery after allo-HCT. Here, we visualized the kinetics of neutrophil and platelet recovery and the impact on outcomes using multistate models with transplant registry data. We also compared the effects of different graft sources.
  
  Methods: We analyzed Japanese nationwide registry data of adult patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in complete remission who underwent first allo-HCT from 2010 to 2022. Second transplantation was treated as a censoring event. Transitional changes of the population with neutrophil &lt;0.5×109/L (state 0), neutrophil ≥0.5×109/L and platelet &lt;20×109/L (state 1), 20×109/L≤ platelet &lt;50×109/L (state 2), and platelet ≥50×109/L (state 3), death, relapse, and non-relapse mortality (NRM) were estimated by multistate model analysis using transition probability plot and proportional transition hazard model. The effects of hematopoietic recovery on mortality, relapse, and NRM were estimated by Simon-Makuch plot and proportional hazard model with time-dependent covariates. Influences of the background factors (age, recipient sex, performance status, comorbidity, diagnoses, disease risk, graft sources, ABO major mismatch, conditioning intensity, and year of transplantation) were adjusted.
  
  Results: A total of 9105 patients (5802 AML and 3303 ALL) were extracted from the database. The number of the transplant sources were: 2398 HLA-matched unrelated bone marrow (uBM), 782 HLA-matched related BM (rBM), 326 HLA-matched unrelated peripheral-blood stem cells (uPB), 1283 HLA-matched rPB, 622 HLA-haploidentical PB (Haplo), and 3694 single-unit cord blood (CB). The median age at allo-HCT was 49 (range, 16-85) years. Neutrophil ≥0.5×109/L at day 60, platelet ≥20×109/L and ≥50×109/L at day 100 were 99%, 91%, and 85% in uBM, 99%, 96%, and 92% in rBM, 99%, 95%, and 90% in uPB, 99%, 96%, and 93% in rPB, 98%, 91%, and 84% in Haplo, and 94%, 87%, and 82% in CB, respectively. Multistate model analysis with the entire patient population showed that the proportions in states 0, 1, 2, 3, relapse, and NRM were 1.4%, 9.9%, 7.4%, 77%, 1.3%, and 3.4% at day 60; and 0.1%, 3.8%, 4.3%, 80%, 5.4%, and 6.6% at day 120, respectively. Patients surviving without adequate platelet recovery (the sum of states 0, 1, and 2) was significantly higher in CB (25%) than in other sources (11-13%) at day 60. Interestingly, the difference became marginal at day 120 (8.3% in CB, and 6.5-8.7% in other sources). Survival probabilities by the Simon-Makuch method in states 0, 1, 2, and 3 were 83%, 93%, 98%, and 100% at day 60, and 44%, 71%, 91%, and 98% at day 120, respectively (P&lt;0.001). Time-dependent covariate analysis showed that the hazard ratios (HRs) of the patients in states 0, 1, and 2 (vs. state 3) were 40, 5.3, and 2.4 for mortality; 57, 7.6, and 3.1 for NRM (all P&lt;0.001), respectively, after adjustment for the background factors. The NRM causes of patients in states 1 and 2 were infection (24%), organ failure (19%), SOS/TMA (12%), and acute GVHD (10%), with the proportion of SOS/TMA and acute GVHD being more than double that of patients in state 3. Multistate model analysis showed that although the transition probabilities (TPs) to mortality from states 1 and 2 were higher in CB (HR 1.4 and 1.7, respectively) compared with uBM, the TP to mortality from state 3 was significantly lower in CB (HR 0.86; P=0.008; vs. uBM) with lower trends for both relapse and NRM.
  
  Conclusions: In this largest retrospective study on hematopoietic recovery to date, the kinetics of survivors without platelet recovery and the detrimental impact of thrombocytopenia on overall mortality and NRM were clearly demonstrated. SOS/TMA and acute GVHD had a greater influence on the NRM of thrombocytopenic patients. Although the platelet recovery was delayed in CB, the proportion of survivors with thrombocytopenia at day 120 was comparable to other sources. The higher risk for mortality in CB was transient, and the risk in CB became less than in uBM after platelet recovery (≥50×109/L). This analysis provides baseline data for future studies of hematopoietic recovery.
• HIV陽性者における性感染症の実態
  松川 敏大; 遠藤 知之; 長井 惇; 宮島 徹; 須藤 啓斗; 長谷川 祐太; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳
  日本エイズ学会誌, 26, 3, 132, 138, (一社)日本エイズ学会, Aug. 2024
  Japanese
• 今月の症例 腎移植30年後に発症した中枢神経原発移植後リンパ増殖性疾患の1例
  石川 楓; 白井 慎一; 上床 尚; 岩田 育子; 松島 理明; 松川 敏大; 山口 秀; 矢口 裕章; 外丸 詩野; 矢部 一郎
  日本内科学会雑誌, 113, 6, 980, 985, (一社)日本内科学会, Jun. 2024
  Japanese, 症例は40歳代女性で、意識障害、運動性失語を主訴とし不全型Gerstmann症候群を呈していた。30年前に生体腎移植を行い免疫抑制剤長期内服中であった。頭部MRIで両側前頭葉および頭頂葉白質に多発する腫瘤性病変、血液検査・髄液検査でEBV-DNA-PCR陽性、18F-FDG-PETの集積亢進を認め、右頭頂葉の生検より、中枢神経原発移植後リンパ増殖性疾患(PCNS-PTLD)の確定診断を得た。脳生検後にベタメタゾン投与を行ったが、midline shiftを認め意識状態が悪化した。免疫抑制剤を中止し全脳照射を行った結果、病変の縮小、midline shiftや意識状態の改善を得た。現在、失語は残存するがADLは可能で、免疫抑制剤中止後も移植腎の機能は保たれている。移植10年以上経過後のPTLD発症例は稀であるが、移植後患者で新規神経症状が出現した場合、PCNS-PTLDを念頭に置いてEBV-DNA測定や脳生検を行う必要があると考えられた。
• Relative impact of THPO mutation causing hereditary thrombocythemia.
  Hiroyuki Kimura; Masahiro Onozawa; Toshihiro Matsukawa; Hideki Goto; Takeshi Kondo; Takanori Teshima
  Experimental hematology, 104208, 104208, 26 Mar. 2024, [International Magazine]
  English, Scientific journal, Germline mutations of THPO were reported as causes of hereditary thrombocythemia. Six previously reported distinct sites of the mutation were clustered at the 5'-untranslated region or the exon 3 splicing donor site of the THPO gene. Each mutation was identified in an independent pedigree and the difference in the mutations were not compared. We cloned 6 distinct THPO mutations (THPO c.-47delG, THPO c.-31G>T, THPO c.13G>A, THPO c.13+1G>A, THPO c.13+2T>C, and THPO c.13+5G>A) and compared the molecular mechanisms that underlie the increased production of THPO protein. At the transcript level, all of the mutations except THPO c.-47delG showed an exon 3 skipping transcript including 2 mutations (THPO c.-31G>T and THPO c.13+5G>A) that were distant from the splicing donor site. THPO c.-47delG showed the same full-length transcript as that of the wild-type transcript. At the protein level, all mutations resulted in a higher level of production of THPO protein compared to wild-type THPO. There are only two distinct patterns of mechanisms for increased production of THPO: 1) exon 3 skipping that deleted upstream suppressive open reading frame (ORF) 7 and 2) one base deletion that shifted ORF7 to connect to the initial codon of THPO in-frame. The common mechanisms of hereditary thrombocytosis due to THPO mutation are unleashed THPO translation that is usually suppressed by upstream out-of-frame ORF7.
• Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
  Naoki Miyashita; Masahiro Onozawa; Toshihiro Matsukawa; Akio Mori; Daisuke Hidaka; Koichiro Minauchi; Akio Shigematsu; Junichi Hashiguchi; Tetsuyuki Igarashi; Yasutaka Kakinoki; Yutaka Tsutsumi; Makoto Ibata; Kentaro Wakasa; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Satoshi Iyama; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
  British journal of haematology, 18 Jan. 2024, [International Magazine]
  English, Scientific journal
• Psoriasiform graft-versus-host disease with distal sweat duct involvement as the diagnostic histopathological feature
  Nakazato, S.; Takashima, S.; Matsukawa, T.; Anan, T.; Ujiie, H.; Matsuno, Y.
  Journal of Dermatology, 2024
  Scientific journal
• FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML
  Matsukawa, T.; Onozawa, M.; Kondo, T.; Kanaya, M.; Hidaka, D.; Ota, S.; Mori, A.; Shigematsu, A.; Miyagishima, T.; Kakinoki, Y.; Hashiguchi, J.; Yamamoto, S.; Yamamoto, M.; Wakasa, K.; Takahata, M.; Ishihara, T.; Haseyama, Y.; Fujimi, A.; Igarashi, T.; Sarashina, T.; Iyama, S.; Kobayashi, R.; Sakai, H.; Fujimoto, K.; Inamura, J.; Kanisawa, Y.; Hirabayashi, S.; Endo, T.; Hashimoto, D.; Teshima, T.
  Annals of Hematology, 2024
  Scientific journal
• Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection.
  Katsuto Takenaka; Shigeo Fuji; Toshihiro Matsukawa; Naoyuki Uchida; Takeshi Kobayashi; Masatsugu Tanaka; Takahide Ara; Kazuhiro Ikegame; Yukiyasu Ozawa; Yoshinobu Kanda; Masashi Sawa; Yumiko Maruyama; Takahiro Fukuda; Hirohisa Nakamae; Takafumi Kimura; Masao Ogata; Sachiko Seo; Yoshiko Atsuta; Keitaro Matsuo; Hideki Nakasone
  Annals of hematology, 103, 1, 285, 296, Jan. 2024, [International Magazine]
  English, Scientific journal, Cytomegalovirus (CMV) infection is a major infectious complication following allogeneic hematopoietic cell transplantation (allo-HCT). Although letermovir (LMV) prophylaxis dramatically reduces the incidence of early clinically significant CMV (csCMV) infection, it remains unclear whether it has a beneficial effect on nonrelapse mortality (NRM) and overall survival (OS). Herein, we evaluated the impact of LMV prophylaxis on posttransplant outcomes using the registry database of the Japanese Society for Transplantation and Cellular Therapy. Adult patients who underwent allo-HCT between 2017 and 2019 were analyzed (n = 6004). LMV prophylaxis was administered to 1640 patients (LMV group) and it significantly reduced the incidence of csCMV infection compared with those not administered LMV prophylaxis (15.4% vs 54.1%; p < 0.01). However, it did not improve the 1-year NRM (hazard ratio [HR], 0.93; p = 0.40) and OS (HR, 0.96; p = 0.49). In the LMV group, 74 patients had breakthrough csCMV infection and showed inferior NRM (HR, 3.44; p < 0.01) and OS (HR, 1.93; p = 0.02) compared with those without infection. After completing LMV prophylaxis, 252 patients had late csCMV infection and showed inferior NRM (HR, 1.83; p < 0.01) and OS (HR, 1.58; p < 0.01). Our findings suggest that managing breakthrough and late csCMV infections is important for improving long-term outcomes.
• Hereditary thrombocythemia due to splicing donor site mutation of THPO in a Japanese family.
  Hiroyuki Kimura; Masahiro Onozawa; Junichi Hashiguchi; Daisuke Hidaka; Minoru Kanaya; Toshihiro Matsukawa; Hiromi Okada; Takeshi Kondo; Yoshihiro Matsuno; Takanori Teshima
  Annals of hematology, 103, 1, 89, 96, Jan. 2024, [International Magazine]
  English, Scientific journal, Thrombopoietin (THPO) is an essential factor for platelet production. Hereditary thrombocythemia (HT) is caused by a germline mutation of THPO, MPL, or JAK2 and is inherited in an autosomal-dominant manner. We identified a Japanese family with HT due to a point mutation of the splicing donor site of the THPO gene (THPO c.13 + 1G > A). Bone marrow biopsy showed increased megakaryocytes mimicking essential thrombocythemia. One affected family member developed chronic myeloid leukemia. We cloned the mutation and developed mutated and wild type THPO expression vectors. Molecular analysis showed that the mutation causes an exon 3 skipping transcript of THPO that abrogates a suppressive untranslated upstream open reading frame. Although the transcript levels of THPO mRNA were comparable, mutated transcripts were more efficiently translated and THPO protein expression was significantly higher than that of the wild type.
• Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
  Preeti Prerna M Vaswani; Masahiro Onozawa; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Toshihiro Matsukawa; Atsushi Yasumoto; Souichi Shiratori; Hideki Goto; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
  Bone marrow transplantation, 58, 12, 1397, 1399, 05 Sep. 2023, [International Magazine]
  English
• Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
  Hiroyuki Kimura; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Hideki Goto; Tomoyuki Endo; Satoshi Oguri; Shinichi Fujisawa; Akio Mori; Takeshi Kondo; Daisuke Hidaka; Kohei Okada; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Junichi Hashiguchi; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takanori Teshima
  Annals of hematology, 102, 11, 3103, 3113, 19 Aug. 2023, [International Magazine]
  English, Scientific journal, IKZF1 deletion is a recurrent genomic alteration in B-cell acute lymphoblastic leukemia (B-ALL) and is divided into dominant-negative (DN) and loss of function (LOF) deletions. The prognostic impact of each deletion has not been fully elucidated. We retrospectively analyzed 117 patients with adult B-ALL including 60 patients with BCR::ABL1-positive B-ALL and 57 patients with BCR::ABL1-negative B-ALL by the fluorescence in situ hybridization (FISH) method for IKZF1 deletion and multiplex PCR for the 4 most common IKZF1 deletions (∆4-7, ∆2-7, ∆2-8, and ∆4-8). Samples, in which IKZF1 deletion was detected by FISH but a specific type of deletion was not identified by the PCR, were categorized as "other." Patients were classified into a DN group that had at least 1 allele of ∆4-7 (n = 23), LOF and other group (n = 40), and wildtype group (n = 54). DN type IKZF1 deletions were found in 33.3% of BCR::ABL1-positive cases and 5.2% of BCR::ABL1-negative cases. LOF and other type IKZF1 deletions were found in 43.4% of BCR::ABL1-positive cases and 24.6% of BCR::ABL1-negative cases. Patients with the DN group showed significantly higher overall survival (OS) than that of the LOF and other and WT groups (P = 0.011). Multivariate analysis including age, WBC counts, complex karyotype, and DN type IKZF1 deletion showed that the DN type of IKZF1 deletion (HR = 0.22, P = 0.013) had a positive impact and age ≥ 65 (HR = 1.92, P = 0.029) had a negative impact on OS. The prognostic impact of IKZF1 deletion depends on the type of deletion and DN type of IKZF1 deletion showed better prognosis in adult B-ALL patients.Clinical trial registration This study was part of a prospective observational study (Hokkaido Leukemia Net, UMIN000048611). It was conducted in compliance with ethical principles based on the Helsinki Declaration and was approved by the institutional review board of Hokkaido University Hospital (#015-0344).
• Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
  Toru Miyajima; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Hideki Goto; Junichi Sugita; Shinichi Fujisawa; Daisuke Hidaka; Reiki Ogasawara; Akio Mori; Satomi Matsuoka; Akio Shigematsu; Kentaro Wakasa; Ikumi Kasahara; Tomoyuki Saga; Junichi Hashiguchi; Yukari Takeda; Makoto Ibata; Tsutsumi Yutaka; Katsuya Fujimoto; Takeshi Kondo; Takanori Teshima
  European journal of haematology, 111, 4, 620, 627, 19 Jul. 2023, [International Magazine]
  English, Scientific journal, OBJECTIVES: The cryptic fusion oncogene NUP98::NSD1 is known to be associated with FLT3-ITD mutation in acute myeloid leukemia (AML), and an independent poor prognostic factor in pediatric AML. However, there are little data regarding the clinical significance of NUP98::NSD1 in adult cohort. METHODS: We conducted a multicenter retrospective study to investigate the prevalence, clinical characteristics, and prognostic impact of NUP98::NSD1 in adult FLT3-ITD-positive AML patients. RESULTS: In a total of 97 FLT3-ITD-positive AML patients, six cases (6.2%) were found to harbor the NUP98::NSD1 fusion transcript. NUP98::NSD1 positive cases had significantly higher platelet counts and a higher frequency of FAB-M4 morphology than NUP98::NSD1 negative cases. NUP98::NSD1 was found to be mutually exclusive with NPM1 mutation, and was accompanied by the WT1 mutation in three of the six cases. The presence of NUP98::NSD1 fusion at the time of diagnosis predicted poor response to cytarabine-anthracycline-based intensive induction chemotherapy (induction failure rate: 83% vs. 36%, p = .038). Five of the six cases with NUP98::NSD1 underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two of the five cases have successfully maintained remission, with one of them being rescued through a second HSCT. CONCLUSIONS: Detecting NUP98::NSD1 in adult FLT3-ITD-positive AML is crucial to recognizing chemotherapy-resistant group.
• NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia
  Toshihiro Matsukawa; Mianmian Yin; Nupur Nigam; Vijay Negi; Li Li; Donald Small; Yuelin J. Zhu; Robert L. Walker; Paul S. Meltzer; Peter D. Aplan
  Leukemia, 37, 7, 1545, 1548, 05 May 2023, [International Magazine]
  English, Scientific journal
• Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis.
  Shota Yokoyama; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Toshihiro Matsukawa; Hideki Goto; Shinichi Fujisawa; Kosuke Miki; Daisuke Hidaka; Junichi Hashiguchi; Kentaro Wakasa; Makoto Ibata; Yukari Takeda; Akio Shigematsu; Katsuya Fujimoto; Yutaka Tsutsumi; Akio Mori; Toshimichi Ishihara; Yasutaka Kakinoki; Takeshi Kondo; Daigo Hashimoto; Takanori Teshima
  British journal of haematology, 201, 6, 1144, 1152, 17 Apr. 2023, [International Magazine]
  English, Scientific journal, Recent advances in next-generation sequencing (NGS) have enabled the detection of subclinical minute FLT3-ITD. We selected 74 newly diagnosed, cytogenetically normal acute myeloid leukaemia (AML) samples in which FLT3-ITD was not detected by gel electrophoresis. We sequenced them using NGS and found minute FLT3-ITDs in 19 cases. We compared cases with clinically relevant FLT3-ITD (n = 37), cases with minute FLT3-ITD (n = 19) and cases without detectable FLT3-ITD (n = 55). Molecular characteristics (location and length) of minute FLT3-ITD were similar to those of clinically relevant FLT3-ITD. Survival of cases with minute FLT3-ITD was similar to that of cases without detectable FLT3-ITD, whereas the relapse rate within 1 year after onset was significantly higher in cases with minute FLT3-ITD. We followed 18 relapsed samples of cases with clinically FLT3-ITD-negative at diagnosis. Two of 3 cases with minute FLT3-ITD relapsed with progression to clinically relevant FLT3-ITD. Two of 15 cases in which FLT3-ITD was not detected by NGS relapsed with the emergence of minute FLT3-ITD, and one of them showed progression to clinically relevant FLT3-ITD at the second relapse. We revealed the clonal dynamics of subclinical minute FLT3-ITD in clinically FLT3-ITD-negative AML. Minute FLT3-ITD at the initial AML can expand to become a dominant clone at relapse.
• Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
  Naoki Miyashita; Masahiro Onozawa; Shota Yoshida; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Shinichi Fujisawa; Akio Mori; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takeshi Kondo; Takanori Teshima
  International journal of hematology, 118, 1, 36, 46, 28 Feb. 2023, [Domestic magazines]
  English, Scientific journal, Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more. For CEBPA, 86.7% of the patients with biallelic mutation and 9.1% of patients with the single allele mutation had in-frame mutations in the bZIP domain, which were strongly associated with a favorable prognosis. Multivariate analysis showed that age < 65 years, FLT3-ITD and CEBPA bZIP in-frame mutation were independent prognostic factors. The results suggest that analyzing these gene mutations at diagnosis can inform selection of the optimal intensity of therapy for patients with CN-AML.
• Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
  Shota Yoshida; Masahiro Onozawa; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Akio Mori; Daisuke Hidaka; Koichiro Minauchi; Akio Shigematsu; Junichi Hashiguchi; Tetsuyuki Igarashi; Yasutaka Kakinoki; Yutaka Tsutsumi; Makoto Ibata; Hajime Kobayashi; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Shuichi Ota; Takeshi Kondo; Takanori Teshima
  International journal of hematology, 117, 4, 544, 552, 26 Dec. 2022, [Domestic magazines]
  English, Scientific journal, Complex karyotype acute myeloid leukemia (CK-AML) has been classified as an adverse-risk subtype. Although a few reports have further classified CK-AML as typical (including monosomy of chromosomes 5, 7 and 17 or deletion of 5q, 7q and/or 17p) or atypical, the clinical features of these subtypes in Japanese patients remain unclear. We retrospectively analyzed a total of 115 patients with CK-AML, including 77 with typical CK-AML and 38 with atypical CK-AML. Median overall survival (OS) was significantly shorter in patients with typical CK-AML than atypical CK-AML (143 days vs. 369 days, P = 0.009). Among patients with typical CK-AML, those with monosomy 17 or deletion of 17p had significantly shorter OS than patients without such abnormalities (105 days vs. 165 days, P = 0.033). TP53 mutations were more predominant in patients with typical CK-AML than in patients with atypical CK-AML (69.7% vs. 32.4%, P < 0.001). Patients with typical CK-AML had a poor prognosis regardless of TP53 mutation status. Among patients with atypical CK-AML, however, prognosis was worse for those with the TP53 mutation than those without the mutation. In conclusion, prognosis is extremely poor for both typical CK-AML and atypical CK-AML with TP53 mutation.
• Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context
  Toshihiro Matsukawa; Mianmian Yin; Timour Baslan; Yang Jo Chung; Dengchao Cao; Ryan Bertoli; Yuelin J. Zhu; Robert L. Walker; Amy Freeland; Erik Knudsen; Scott W. Lowe; Paul S. Meltzer; Peter D. Aplan
  The FASEB Journal, 36, 9, e22430, Sep. 2022, [International Magazine]
  English, Scientific journal, Minichromosome maintenance proteins (Mcm2-7) form a hexameric complex that unwinds DNA ahead of a replicative fork. The deficiency of Mcm proteins leads to replicative stress and consequent genomic instability. Mice with a germline insertion of a Cre cassette into the 3'UTR of the Mcm2 gene (designated Mcm2Cre ) have decreased Mcm2 expression and invariably develop precursor T-cell lymphoblastic leukemia/lymphoma (pre-T LBL), due to 100-1000 kb deletions involving important tumor suppressor genes. To determine whether mice that were protected from pre-T LBL would develop non-T-cell malignancies, we used two approaches. Mice engrafted with Mcm2Cre/Cre Lin- Sca-1+ Kit+ hematopoietic stem/progenitor cells did not develop hematologic malignancy; however, these mice died of hematopoietic stem cell failure by 6 months of age. Placing the Mcm2Cre allele onto an athymic nu/nu background completely prevented pre-T LBL and extended survival of these mice three-fold (median 296.5 vs. 80.5 days). Ultimately, most Mcm2Cre/Cre ;nu/nu mice developed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). We identified recurrent deletions of 100-1000 kb that involved genes known or suspected to be involved in BCP-ALL, including Pax5, Nf1, Ikzf3, and Bcor. Moreover, whole-exome sequencing identified recurrent mutations of genes known to be involved in BCP-ALL progression, such as Jak1/Jak3, Ptpn11, and Kras. These findings demonstrate that an Mcm2Cre/Cre hypomorph can induce hematopoietic dysfunction via hematopoietic stem cell failure as well as a "deletor" phenotype affecting known or suspected tumor suppressor genes.
• Cytomegalovirus gastroenteritis in patients with acute graft-versushost disease
  Yu Akahoshi; Shun Ichi Kimura; Yuma Tada; Toshihiro Matsukawa; Masaharu Tamaki; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Hirohisa Nakamae; Takuro Kuriyama; Ken Ichi Matsuoka; Takashi Ikeda; Takafumi Kimura; Takahiro Fukuda; Yoshinobu Kanda; Yoshiko Atsuta; Makoto Murata; Seitaro Terakura; Hideki Nakasone
  Blood Advances, 6, 2, 574, 584, 25 Jan. 2022, [International Magazine]
  English, Scientific journal
• Light-chain amyloid myopathy isolated to skeletal muscles: A case report
  Toshihiro Matsukawa; Katsuki Eguchi; Ichizo Nishino; Kohei Okada; Kazuo Oshimi; Takuto Miyagishima
  Clinical Case Reports, 8, 12, 2869, 2873, Dec. 2020, [International Magazine]
  English, Scientific journal
• Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma
  Toshihiro Matsukawa; Keito Suto; Minoru Kanaya; Koh Izumiyama; Koichiro Minauchi; Shota Yoshida; Hisashi Oda; Takuto Miyagishima; Akio Mori; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
  Annals of Hematology, 99, 12, 2859, 2868, Dec. 2020, [International Magazine]
  English, Scientific journal
• Clinical and molecular consequences of fusion genes in myeloid malignancies
  Toshihiro Matsukawa; Peter D. Aplan
  Stem Cells, 38, 11, 1366, 1374, Oxford University Press (OUP), 01 Nov. 2020, [International Magazine]
  English, Scientific journal, Abstract
  
  Leukemias are heterogeneous diseases characterized by aberrant hematopoietic stem and progenitor cells (HSPCs). Oncogenic fusion genes and proteins, produced via gross chromosomal rearrangements, such as chromosomal translocation, insertion, and inversion, play important roles in hematologic malignancies. These oncoproteins alter fundamental cellular properties, such as self-renewal, differentiation, and proliferation, and confer leukemogenic potential to HSPCs. In addition to providing fundamental insights into the process of leukemic transformation, these fusion genes provide targets for treatment and monitoring of myeloid leukemias. Furthermore, new technologies such as next-generation sequencing have allowed additional insights into the nature of leukemic fusion genes. In this review, we discuss the history, biologic effect, and clinical impact of fusion genes in the field of myeloid leukemias.
• HLA loci predisposing to immune TTP in Japanese: Potential role of the shared ADAMTS13 peptide bound to different HLA-DR
  Kazuya Sakai; Masataka Kuwana; Hidenori Tanaka; Kazuyoshi Hosomichi; Atsushi Hasegawa; Hiroki Uyama; Kenji Nishio; Takashi Omae; Masakatsu Hishizawa; Masashi Matsui; Koji Iwato; Akinao Okamoto; Kazuki Okuhiro; Yukiko Yamashita; Masataka Itoh; Hanae Kumekawa; Naoki Takezako; Noriaki Kawano; Toshihiro Matsukawa; Haruna Sano; Kazuiku Ohshiro; Kunio Hayashi; Yasunori Ueda; Toshiki Mushino; Yoshiyuki Ogawa; Yuji Yamada; Mitsuru Murata; Masanori Matsumoto
  Blood, 135, 26, 2413, 2419, 25 Jun. 2020, [International Magazine]
  English, Scientific journal
• A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia
  Mianmian Yin; Timour Baslan; Robert L. Walker; Yuelin J. Zhu; Amy Freeland; Toshihiro Matsukawa; Sriram Sridharan; André Nussenzweig; Steven C. Pruitt; Scott W. Lowe; Paul S. Meltzer; Peter D. Aplan
  JCI Insight, 4, 23, 05 Dec. 2019, [International Magazine]
  English, Scientific journal
• 薬物性肝障害に引き続き発症したと思われる再生不良性貧血
  長井 惇; 松川 敏大; 須藤 啓斗; 押味 和夫; 宮城島 拓人
  臨床血液, 60, 7, 779, 784, (一社)日本血液学会-東京事務局, Jul. 2019
  Japanese
• The phytosphingosine-CD300b interaction promotes zymosan-induced, nitric oxide–dependent neutrophil recruitment
  Mariko Takahashi; Kumi Izawa; Makoto Urai; Yoshinori Yamanishi; Akie Maehara; Masamichi Isobe; Toshihiro Matsukawa; Ayako Kaitani; Ayako Takamori; Shino Uchida; Hiromichi Yamada; Masakazu Nagamine; Tomoaki Ando; Toshiaki Shimizu; Hideoki Ogawa; Ko Okumura; Yuki Kinjo; Toshio Kitamura; Jiro Kitaura
  Science Signaling, 12, 564, 15 Jan. 2019, [International Magazine]
  English, Scientific journal
• [Aplastic anemia following drug-induced liver injury].
  Jun Nagai; Toshihiro Matsukawa; Keito Suto; Kazuo Oshimi; Takuto Miyagishima
  [Rinsho ketsueki] The Japanese journal of clinical hematology, 60, 7, 779, 784, 2019, [Domestic magazines]
  Japanese, Scientific journal, Aplastic anemia (AA), a hematopoietic disorder characterized by hypocellular bone marrow, is caused by immunologically-mediated hematopoietic stem cell injury. Viral infection is hypothesized as the underlying cause of hepatitis-associated AA, although its mechanism is still unclear. This report describes a case of AA following suspected drug-induced liver injury (DILI). An 18-year-old man developed severe liver dysfunction after taking oral over-the-counter drugs. The patient was diagnosed with suspected DILI based on drug-induced lymphocyte stimulation test and liver biopsy results. Although liver dysfunction improved after a course of steroid pulse therapy and liver supporting therapy, the man gradually developed pancytopenia within 3 months of DILI diagnosis, prompting the diagnosis of AA following DILI. Paroxysmal nocturnal hemoglobinuria-type cells were detected by high-sensitivity flow cytometry. Immunosuppressive therapy with antithymocyte globulin and cyclosporin was administered, with pancytopenia improvement. To the best of our knowledge, this is the first report in the literature with a case of AA following DILI, and we believe it is important for evaluating the pathogenesis of drug-induced and hepatitis-associated AA.
• Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy.
  Toshihiro Matsukawa; Keito Suto; Hiroaki Miyoshi; Kazuo Oshimi; Koichi Ohshima; Takuto Miyagishima
  Journal of clinical and experimental hematopathology : JCEH, 58, 4, 184, 187, 13 Dec. 2018, [Domestic magazines]
  English, Scientific journal
• Leukocyte mono-immunoglobulin-like receptor 8 (LMIR8)/CLM-6 is an FcRγ-coupled receptor selectively expressed in mouse tissue plasmacytoid dendritic cells
  Ayako Kaitani; Kumi Izawa; Akie Maehara; Masamichi Isobe; Ayako Takamori; Toshihiro Matsukawa; Mariko Takahashi; Yoshinori Yamanishi; Toshihiko Oki; Hiromichi Yamada; Masakazu Nagamine; Shino Uchida; Koichiro Uchida; Tomoaki Ando; Keiko Maeda; Nobuhiro Nakano; Toshiaki Shimizu; Toshiyuki Takai; Hideoki Ogawa; Ko Okumura; Toshio Kitamura; Jiro Kitaura
  Scientific Reports, 8, 1, 01 Dec. 2018
  Scientific journal
• Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation
  Yoshihiro Inamoto; Tomohiro Matsuda; Ken Tabuchi; Saiko Kurosawa; Hideki Nakasone; Hisakazu Nishimori; Satoshi Yamasaki; Noriko Doki; Koji Iwato; Takehiko Mori; Satoshi Takahashi; Hiromasa Yabe; Akio Kohno; Hirohisa Nakamae; Toru Sakura; Hisako Hashimoto; Junichi Sugita; Hiroatsu Ago; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Takuya Yamashita; Minako Iida; Takayuki Ishikawa; Keiichi Isoyama; Masami Inoue; Kumi Oshima; Shinichiro Okamoto; Rika Sakai; Masaaki Shiohara; Shuichi Taniguchi; Hideki Nakasone; Makoto Hirokawa; Shin Fujisawa; Yasuo Horikoshi; Masato Masuda; Hidetsugu Mihara; Yuki Asano-Mori; Yasushi Ishida; Aika Seto; Nahoko Hatsumi; Akira Hayakawa; Atsushi Sato; H. Nishimori; Masako Toyosaki; Koichi Miyamura; Chikako Kiyotani; Raine Tatara; Toshihiro Matsukawa; Satoshi Yoshioka
  Blood Advances, 2, 15, 1901, 1913, 14 Aug. 2018
  Scientific journal
• Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia
  Shuichi Ota; Toshihiro Matsukawa; Satoshi Yamamoto; Shinichi Ito; Motohiro Shindo; Kazuya Sato; Takeshi Kondo; Kyuhei Kohda; Hajime Sakai; Akio Mori; Tohru Takahashi; Hiroshi Ikeda; Hiroyuki Kuroda; Yoshihito Haseyama; Masaki Yamamoto; Takeo Sarashina; Makoto Yoshida; Ryoji Kobayashi; Mitsufumi Nishio; Toshimichi Ishihara; Yasuo Hirayama; Yasutaka Kakinoki; Hajime Kobayashi; Takashi Fukuhara; Masahiro Imamura; Mitsutoshi Kurosawa
  European Journal of Haematology, 101, 1, 95, 105, Jul. 2018
  Scientific journal
• The CD300e molecule in mice is an immune-activating receptor
  Masamichi Isobe; Kumi Izawa; Masahiro Sugiuchi; Tamami Sakanishi; Ayako Kaitani; Ayako Takamori; Akie Maehara; Toshihiro Matsukawa; Mariko Takahashi; Yoshinori Yamanishi; Toshihiko Oki; Shino Uchida; Koichiro Uchida; Tomoaki Ando; Keiko Maeda; Nobuhiro Nakano; Hideo Yagita; Toshiyuki Takai; Hideoki Ogawa; Ko Okumura; Toshio Kitamura; Jiro Kitaura
  Journal of Biological Chemistry, 293, 10, 3793, 3805, 09 Mar. 2018
  Scientific journal
• Recurrent invasive pneumococcal disease in a patient with IgG-κ smoldering multiple myeloma
  千葉雅尋; 押味和夫; 松川敏大; 岡田耕平; 宮城島拓人
  臨床血液, 59, 1, 40, 44, (一社)日本血液学会-東京事務局, Jan. 2018
  Japanese
• Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment
  Kumi Izawa; Akie Maehara; Masamichi Isobe; Yuka Yasuda; Makoto Urai; Yasutaka Hoshino; Keigo Ueno; Toshihiro Matsukawa; Mariko Takahashi; Ayako Kaitani; Emiko Shiba; Ayako Takamori; Shino Uchida; Koichiro Uchida; Keiko Maeda; Nobuhiro Nakano; Yoshinori Yamanishi; Toshihiko Oki; David Voehringer; Axel Roers; Susumu Nakae; Junko Ishikawa; Yuki Kinjo; Toshiaki Shimizu; Hideoki Ogawa; Ko Okumura; Toshio Kitamura; Jiro Kitaura
  Scientific Reports, 7, 1, 01 Dec. 2017
  Scientific journal
• 抗レトロウイルス療法中に症候性多発性骨髄腫を発症し、寛解後にplasmablastic lymphoma/plasmacytomaを口腔領域に発症して腫瘍死した一剖検例
  宮城島 拓人; 更科 耕一郎; 山村 貴洋; 松田 宗一郎; 千葉 雅尋; 中野 真太郎; 松川 敏大; 小林 良充; 羽場 真; 高橋 一宏; 寺下 勝巳; 曽我部 進; 小田 寿; 藤盛 真樹; 高橋 達郎
  日本エイズ学会誌, 19, 3, 165, 170, (一社)日本エイズ学会, Aug. 2017
  Japanese, 40歳代男。Men who have Sex with Menで、Human immunodeficiency virus(HIV)陽性が判明し、抗レトロウイルス療法(ART)を開始した。血清学的にIgGλ型多発性骨髄腫、ISS病期分類III期と診断された。HIVに関しては、CD4 1264/μL、HIV-RNA 59 copies/mL あった。ARTを継続しながらボルテゾミブ、デキサメサゾンで治療導入し、自家末梢血幹細胞移植(PBSCT)併用メルファラン大量療法でvery good partial responseを得、レナリドミド維持療法を導入した。維持療法開始10ヵ月後に右頬部に腫脹と疼痛が出現し、口腔側からの頬粘膜の腫脹および圧痛を認めた。病理所見でplasmablastic lymphomaあるいはplasmablastic plasmacytomaと診断された。2度目のPBSCT併用メルファラン大量療法により、腫瘍が消失するも、再び腫瘍の増大を認めた。その後、治療不応となり、以後は疼痛緩和主体となった。多発性骨髄腫を発症してから3年、口腔腫瘍が出現してから1年半で腫瘍死した。剖検にて、腫瘍は右頬部、右腎周囲に広汎な腫瘍塊を認め、左副腎や肺、膵には小巣を認めた。病理学的には多型性、異型性が目立っていた。HIVは最後までコントロールされていた。
• Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation
  Naohiro Miyashita; Tomoyuki Endo; Masahiro Onozawa; Daigo Hashimoto; Takeshi Kondo; Katsuya Fujimoto; Kaoru Kahata; Junichi Sugita; Hideki Goto; Toshihiro Matsukawa; Satoshi Hashino; Takanori Teshima
  Transplant Infectious Disease, 19, 3, Jun. 2017
  Scientific journal
• MALDI-TOF MS in post-transplant bloodstream infections: Reliable identification of causative bacteria in the neutropenic phase
  Kanaya, M.; Hayashi, Y.; Hashimoto, D.; Endo, T.; Sugita, J.; Ohigashi, H.; Hashiguchi, J.; Matsukawa, T.; Matsuoka, S.; Kosugi-Kanaya, M.; Goto, H.; Onozawa, M.; Kahata, K.; Fujimoto, K.; Kondo, T.; Akizawa, K.; Shibuya, H.; Shimizu, C.; Teshima, T.
  Bone Marrow Transplantation, 52, 5, 2017
  Scientific journal
• Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD
  Toshihiro Matsukawa; Daigo Hashimoto; Junichi Sugita; Seitarou Nakazawa; Takae Matsushita; Haruhiko Kashiwazaki; Hideki Goto; Masahiro Onozawa; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Yutaka Yamazaki; Takanori Teshima
  International Journal of Hematology, 104, 1, 117, 124, 01 Jul. 2016
  Scientific journal
• Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation
  Toshihiro Matsukawa; Kumi Izawa; Masamichi Isobe; Mariko Takahashi; Akie Maehara; Yoshinori Yamanishi; Ayako Kaitani; Ko Okumura; Takanori Teshima; Toshio Kitamura; Jiro Kitaura
  Gut, 65, 5, 777, 787, May 2016
  Scientific journal
• 【マスト細胞の分化と機能の制御】LMIR3/CD300fによる実験的腸炎の制御 LMIR3とセラミドの結合はATPによる腸管マスト細胞の活性化を抑制する
  松川 敏大; 北村 俊雄; 北浦 次郎
  臨床免疫・アレルギー科, 64, 4, 374, 379, (有)科学評論社, Oct. 2015
  Japanese
• Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells
  Fumio Nakahara; Jiro Kitaura; Tomoyuki Uchida; Chiemi Nishida; Katsuhiro Togami; Daichi Inoue; Toshihiro Matsukawa; Yuki Kagiyama; Yutaka Enomoto; Kimihito C. Kawabata; Lai Chen-Yi; Yukiko Komeno; Kumi Izawa; Toshihiko Oki; Genta Nagae; Yuka Harada; Hironori Harada; Makoto Otsu; Hiroyuki Aburatani; Beate Heissig; Koichi Hattori; Toshio Kitamura
  Blood, 123, 25, 3932, 3942, 19 Jun. 2014
  Scientific journal
• Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation
  Kumi Izawa; Masamichi Isobe; Toshihiro Matsukawa; Shinichi Ito; Akie Maehara; Mariko Takahashi; Yoshinori Yamanishi; Ayako Kaitani; Toshihiko Oki; Ko Okumura; Toshio Kitamura; Jiro Kitaura
  Journal of Allergy and Clinical Immunology, 133, 1, 270, 273.e7, Jan. 2014
  Scientific journal
• Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition
  Mariko Takahashi; Kumi Izawa; Jun Ichi Kashiwakura; Yoshinori Yamanishi; Yutaka Enomoto; Ayako Kaitani; Akie Maehara; Masamichi Isobe; Shinichi Ito; Toshihiro Matsukawa; Fumio Nakahara; Toshihiko Oki; Masunori Kajikawa; Chisei Ra; Yoshimichi Okayama; Toshio Kitamura; Jiro Kitaura
  Journal of Biological Chemistry, 288, 11, 7662, 7675, 15 Mar. 2013
  Scientific journal
• セラミドとマスト細胞〈LMIR3/CD300fはセラミドを認識してマスト細胞の活性化を抑制する〉
  北浦次郎; 伊沢久未; 山西吉典; 前原秋絵; 高橋まり子; 磯部優理; 伊東慎市; 貝谷綾子; 松川敏大; 中原史雄; 沖俊彦; 北村俊雄; 奥村康; 奥村康; 清成寛; 阿部高也
  アレルギー, 62, 9/10, 2013
• Chimerism analyses by sex-chromosome analysis confused relapse with donor cell leukemia after sex-mismatched allo-SCT
  T Matsukawa; A Shigematsu; K Hayasaka; S Fujisawa; S Asanuma; A Yasumoto; H Goto; M Takahata; T Endo; J Tanaka; S Hashino; C Shimizu; M Imamura
  Bone Marrow Transplantation, 47, 12, 1583, 1584, Springer Science and Business Media LLC, Dec. 2012
  Scientific journal
• The Receptor LMIR3 Negatively Regulates Mast Cell Activation and Allergic Responses by Binding to Extracellular Ceramide
  Kumi Izawa; Yoshinori Yamanishi; Akie Maehara; Mariko Takahashi; Masamichi Isobe; Shinichi Ito; Ayako Kaitani; Toshihiro Matsukawa; Takayuki Matsuoka; Fumio Nakahara; Toshihiko Oki; Hiroshi Kiyonari; Takaya Abe; Ko Okumura; Toshio Kitamura; Jiro Kitaura
  Immunity, 37, 5, 827, 839, 16 Nov. 2012
  Scientific journal
• Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice
  Yuki Kagiyama; Jiro Kitaura; Katsuhi Togami; Tomoyuk Uchida; Daichi Inoue; Toshihiro Matsukawa; Kumi Izawa; Kimihito C. Kawabata; Yukiko Komeno; Toshihi Oki; Fumio Nakahara; Katsuak Sato; Hiroyuk Aburatani; Toshio Kitamura
  International Journal of Hematology, 96, 5, 638, 648, Nov. 2012
  Scientific journal
• A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations
  Toshihiro Matsukawa; Hideki Goto; Kenta Takahashi; Shinsuke Asanuma; Atsushi Yasumoto; Mutsumi Takahata; Akio Shigematsu; Tomoyuki Endo; Junji Tanaka; Satoshi Hashino; Shinya Tanaka; Masahiro Imamura
  International Journal of Hematology, 95, 2, 217, 222, Feb. 2012
  Scientific journal
• SMILE療法が奏功した治療抵抗性腸管症型T細胞リンパ腫の1例
  定免渉; 黒田裕行; 酒井俊郎; 松川敏大; 小沼祐一; 野田さや香; 小幡雅彦; 安藤政克; 幸田久平
  旭川赤十字病院医学雑誌, 22, 2010

• Cardiotoxicity in PTCy-based GVHD prophylaxis after HLA-haploidentical HSCT
  松川敏大; 杉田純一; 橋本大吾; 相庭昌之; 岡田耕平; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025
• 大量失血を伴う手術時におけるレナカパビルの血中濃度の推移
  遠藤知之; 田澤佑基; 遠藤知之; 田澤佑基; 新井崇之; 後藤秀樹; 松川敏大; 荒隆英; 長谷川祐太; 長井惇; 森木朝子; 高橋知希; 後藤了一; 後藤秀樹; 松川敏大; 荒隆英; 長谷川祐太; 長井惇; 森木朝子; 高橋知希; 後藤了一; 嶋村剛; 原貴信; 曽山明彦; 江口晋; 豊嶋崇徳; 江口晋; 豊嶋崇徳, 日本エイズ学会誌, 27, 4, 2025
• The Frequency of Blip and the Maintenance Rate of Target Not Detected (TND) in HIV-Positive Individuals Treated with a Two-Drug Regimen
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 須藤啓斗; 須藤啓斗; 宮島徹; 宮島徹; 長井惇; 長井惇; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 27, 2, 2025
• HIV感染者における悪性腫瘍の発生率と予後
  松川敏大; 遠藤知之; 長谷川祐太; 高橋知希; 森木朝子; 長井惇; 後藤秀樹; 豊嶋崇徳; 松川敏大; 遠藤知之; 長谷川祐太; 高橋知希; 森木朝子; 長井惇; 後藤秀樹; 豊嶋崇徳; 遠藤知之, 日本エイズ学会誌, 27, 4, 2025
• Multiplex PCR on Cerebrospinal Fluid to Diagnose Central Nervous System Complications in AIDS Patients
  松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 遠藤知之; 森木朝子; 森木朝子; 長井惇; 長井惇; 宮島徹; 宮島徹; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 27, 3, 2025
• Zanubrutinibが奏効したBing-Neel症候群の1例
  野島慎悟; 野津麟太郎; 堀北風花; 宮島徹; 吉田匠汰; 木村弘幸; 荒隆英; 小笠原励起; 松川敏大; 白鳥聡一; 中川雅夫; 豊嶋崇徳, 臨床血液, 66, 11, 2025
• Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort
  Minoru Kanaya; Yuji Mukai; Mirei Kobayashi; Sayaka Kajikawa; Toma Suzuki; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Masanobu Morioka; Akio Mori; Toshihiro Matsukawa; Masahiro Onozawa; Goichi Yoshimoto; Mitsuru Moriyama; Sunggi Chi; Takanori Teshima; Yosuke Minami; Masato Honmma; Takeshi Kondo, BLOOD, 144, 2930, 2931, 05 Nov. 2024
  English, Summary international conference
• HIV感染合併血友病患者の運動機能評価およびリハビリテーションの有用性
  遠藤 知之; 渡部 恵子; 原田 裕子; 由利 真; 千田 尊子; 後藤 秀樹; 松川 敏大; 荒 隆英; 長谷川 祐太; 宮島 徹; 長井 惇; 森木 朝子; 藤谷 順子; 豊嶋 崇徳, 日本エイズ学会誌, 26, 4, 380, 380, Nov. 2024
  (一社)日本エイズ学会, Japanese
• 簡易懸濁法でドラビリンとドルテグラビルを投与後に血漿中薬物濃度を測定した一例
  田澤 佑基; 松川 敏大; 新井 崇之; 遠藤 知之; 武隈 洋; 菅原 満, 日本エイズ学会誌, 26, 4, 402, 402, Nov. 2024
  (一社)日本エイズ学会, Japanese
• AIDS患者の髄液病原体網羅的解析を目的としたマルチプレックスPCRの有用性についての検討
  松川 敏大; 遠藤 知之; 森木 朝子; 長井 惇; 宮島 徹; 長谷川 祐太; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳, 日本エイズ学会誌, 26, 4, 457, 457, Nov. 2024
  (一社)日本エイズ学会, Japanese
• ART療法が奏効した難治性サイトメガロウイルス腸炎の1例
  長谷川 祐太; 遠藤 知之; 宮島 徹; 長井 惇; 森木 朝子; 松川 敏大; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳, 日本エイズ学会誌, 26, 4, 459, 459, Nov. 2024
  (一社)日本エイズ学会, Japanese
• 北海道ブロック「HIV/AIDS出張研修」 12年間の実践報告
  渡部 恵子; センテノ田村 恵子; 遠藤 知之; 武内 阿味; 熊谷 泰恵; 石田 陽子; 尾谷 ゆか; 山口 みなみ; 北村 末季; 松川 敏大; 長谷川 祐太; 後藤 秀樹; 豊嶋 崇徳; 三宅 亜矢, 日本エイズ学会誌, 26, 4, 514, 514, Nov. 2024
  (一社)日本エイズ学会, Japanese
• 骨腫瘍との鑑別を要したBrown tumorを伴った副甲状腺機能亢進症
  伊藤 悠菜; 亀田 啓; 宮 愛香; 中村 昭伸; 松岡 正剛; 松川 敏大; 渥美 達也, 日本内分泌学会雑誌, 100, 2, 640, 640, Oct. 2024
  (一社)日本内分泌学会, Japanese
• HLA半合致移植を施行したShwachman-Diamond症候群(SDS)を背景とした急性骨髄性白血病
  塚本 しほり; 中川 雅夫; 小野澤 真弘; 南谷 泰仁; 小島 圭祐; 原田 知弥; 荒 隆英; 松川 敏大; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳, 臨床血液, 65, 10, 1329, 1329, Oct. 2024
  (一社)日本血液学会-東京事務局, Japanese
• FLT3阻害薬は投与時期に関わらずFLT3変異AMLの予後を延長する
  松川 敏大; 近藤 健; 日高 大輔; 太田 秀一; 金谷 穣; 盛 暁生; 重松 明男; 宮城島 拓人; 柿木 康孝; 橋口 淳一; 山本 聡; 山本 昌代; 若狭 健太郎; 高畑 むつみ; 石原 敏道; 長谷山 美仁; 藤見 章仁; 五十嵐 哲祥; 更科 岳大; 井山 諭; 小林 良二; 酒井 基; 藤本 勝也; 稲村 純季; 蟹澤 祐司; 平林 真介; 小野澤 真弘; 遠藤 知之; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O1, 5, Oct. 2024
  (一社)日本血液学会, English
• Ph染色体陰性BCR::ABL1陽性急性白血病の頻度と臨床的特徴
  横山 翔大; 小野澤 真弘; 木村 弘幸; 荒 隆英; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 平林 真介; 盛 暁生; 日高 大輔; 橋口 淳一; 若狭 健太郎; 井端 淳; 武田 紫; 重松 明男; 山本 聡; 藤本 勝也; 堤 豊; 石原 敏道; 酒井 基; 柿木 康孝; 小宅 達郎; 近藤 健; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O1, 1, Oct. 2024
  (一社)日本血液学会, English
• ベネトクラクスによる治療を受けた新規診断急性骨髄性白血病の遺伝子変異と予後
  宮下 直樹; 小野澤 真弘; 長井 惇; 吉田 匠汰; 木村 弘幸; 横山 翔大; 松川 敏大; 杉田 純一; 日高 大輔; 小笠原 励起; 盛 暁生; 近藤 健; 柿木 康孝; 重松 明男; 若狭 健太郎; 笠原 郁美; 石原 敏道; 橋口 淳一; 武田 紫; 石尾 崇; 酒井 基; 堤 豊; 藤本 勝也; 井山 諭; 小宅 達郎; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O2, 3, Oct. 2024
  (一社)日本血液学会, English
• NUP98::NSD1融合遺伝子とFLT3-ITD変異を有する成人急性骨髄性白血病の1例
  和田 達也; 田中 淳; 島津 弥生; 岸本 渉; 長井 惇; 松川 敏大; 南谷 泰仁; 竹田 淳恵; 小川 誠司; 高折 晃史; 菱澤 方勝; 森口 寿徳, 日本血液学会学術集会, 86回, P2, 6, Oct. 2024
  (一社)日本血液学会, English
• 成人B細胞性急性リンパ性白血病における複雑核型解析
  木村 弘幸; 小野澤 真弘; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 盛 暁生; 日高 大輔; 杉田 純一; 柿木 康孝; 堤 豊; 山本 聡; 重松 明男; 橋口 淳一; 井端 淳; 横山 翔大; 若狭 健太郎; 長谷山 美仁; 藤本 勝也; 石原 敏道; 酒井 基; 平林 真介; 小宅 達郎; 近藤 健; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O3, 3, Oct. 2024
  (一社)日本血液学会, English
• Case Report; A case of primary central nervous system post-transplant lymphoproliferative disorder 30 years after renal transplantation.
  石川楓; 白井慎一; 上床尚; 岩田育子; 松島理明; 松川敏大; 山口秀; 矢口裕章; 外丸詩野; 矢部一郎, 日本内科学会雑誌, 113, 6, 980, 985, Jun. 2024
  (一社)日本内科学会, Japanese
• Impact of duration of response of prior therapy on therapeutic efficacy of CAR-T therapy in DLBCL
  後藤秀樹; 荒隆英; 大東寛幸; 長谷川祐太; 千葉雅尋; 千丈創; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024
• Low-molecular-weight heparin and the incidence of SOS/VOD during HSCT
  白鳥聡一; 長谷川祐太; 大東寛幸; 荒隆英; 松川敏大; 安本篤史; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024
• Histiocytic lesion arising in hypothalamus of adult diagnosed by endoscopic transnasal biopsy
  伊師雪友; 高桑恵美; 岡田宏美; 松川敏大; 小島圭祐; 遠藤知之; 大木聡悟; 山口秀; 藤村幹, 日本神経内視鏡学会プログラム・抄録集, 31st, 2024
• 略全身の乾癬様紅色局面
  中里 信一; 高島 翔太; 松川 敏大; 阿南 隆; 氏家 英之; 松野 吉宏, 日本皮膚病理組織学会抄録集, 40回, 52, 52, Jan. 2024
  日本皮膚病理組織学会, Japanese
• HIV陽性者における性感染症の実態
  松川 敏大; 遠藤 知之; 長井 惇; 宮島 徹; 須藤 啓斗; 長谷川 祐太; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳, 日本エイズ学会誌, 25, 4, 441, 441, Nov. 2023
  (一社)日本エイズ学会, Japanese
• 2剤療法施行中のHIV陽性者におけるBlipおよびTND(Target Not Detected)維持率の検討
  遠藤 知之; 後藤 秀樹; 松川 敏大; 荒 隆英; 長谷川 祐太; 須藤 啓斗; 宮島 徹; 長井 惇; 豊嶋 崇徳, 日本エイズ学会誌, 25, 4, 498, 498, Nov. 2023
  (一社)日本エイズ学会, Japanese
• 新規発症の急性リンパ性白血病におけるWT1
  松川 敏大; 小野澤 真弘; 長井 惇; 吉田 匠汰; 宮下 直樹; 木村 弘幸; 金谷 穣; 太田 秀一; 盛 暁生; 近藤 健; 柿木 康孝; 皆内 康一郎; 重松 明男; 若狭 健太郎; 橋口 淳一; 石原 敏道; 藤本 勝也; 堤 豊; 井端 淳; 酒井 基; 小宅 達郎; 豊嶋 崇徳, 日本血液学会学術集会, 85回, 395, 395, Oct. 2023
  (一社)日本血液学会, English
• Dominant-negativeタイプのIKZF1欠失が成人B細胞性急性リンパ性白血病に与える影響
  木村 弘幸; 小野澤 真弘; 吉田 匠汰; 宮下 直樹; 松川 敏大; 平林 真介; 後藤 秀樹; 小栗 聡; 藤澤 真一; 盛 暁生; 近藤 健; 日高 大輔; 岡田 耕平; 太田 秀一; 柿木 康孝; 堤 豊; 山本 聡; 宮城島 拓人; 橋口 淳一; 永嶋 貴博; 井端 淳; 横山 翔大; 若狭 健太郎; 長谷山 美仁; 高橋 承吾; 藤本 勝也; 石原 敏道; 酒井 基; 豊嶋 崇徳, 日本血液学会学術集会, 85回, 1095, 1095, Oct. 2023
  (一社)日本血液学会, English
• NPM1変異陽性急性骨髄性白血病におけるDNMT3A R882変異の臨床的意義
  宮下 直樹; 小野澤 真弘; 吉田 匠汰; 長井 惇; 木村 弘幸; 横山 翔大; 松川 敏大; 杉田 純一; 小笠原 励起; 日高 大輔; 盛 暁生; 近藤 健; 松岡 里湖; 重松 明男; 若狭 健太郎; 笠原 郁美; 佐賀 智之; 橋口 淳一; 武田 紫; 井端 淳; 堤 豊; 藤本 勝也; 豊嶋 崇徳, 日本血液学会学術集会, 85回, 1222, 1222, Oct. 2023
  (一社)日本血液学会, English
• 複雑核型を有する初発急性骨髄性白血病の臨床的特徴
  吉田匠汰; 小野澤真弘; 宮下直樹; 木村弘幸; 高橋承吾; 横山翔大; 松川敏大; 近藤健; 豊嶋崇徳, 日本内科学会雑誌, 112, 2023
• 中枢病変を有した成人T細胞性白血病/リンパ腫(ATLL)の1例
  塚本しほり; 清水亜衣; 森祐斗; 横山翔大; 荒隆英; 松川敏大; 白鳥聡一; 中川雅夫; 遠藤知之; 高桑恵美; 加留部謙之輔; 松野吉宏; 豊嶋崇徳, 臨床血液, 64, 7, 2023
• 大腿骨人工骨頭インプラント周囲に発症したALK陰性未分化大細胞型リンパ腫の1例
  森 祐斗; 荒 隆英; 中川 雅夫; 吉田 匠汰; 斎藤 祐美花; 横山 翔大; 松川 敏大; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳, 臨床血液, 63, 11, 1592, 1593, Nov. 2022
  (一社)日本血液学会-東京事務局, Japanese
• Retrospective analysis of allo-SCT for adult T cell leukemia/lymphoma in single institution
  荒隆英; 横山翔大; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022
• Bacillus species bacteremia in patients who underwent hematopoietic stem cell transplant
  森祐斗; 荒隆英; 横山翔大; 松川敏大; 白鳥聡一; 中川雅夫; 遠藤知之; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022
• CRP is a predictive marker of the antifebrile effect of tocilizumab on CRS during CAR-T cell therapy
  横山翔大; 後藤秀樹; 荒隆英; 森祐斗; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022
• VGCV中止による免疫回復にて改善を認めたCMV感染症合併のAIDS症例
  横山翔大; 横山翔大; 遠藤知之; 遠藤知之; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 高橋承吾; 高橋承吾; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 松川敏大; 松川敏大; 後藤秀樹; 後藤秀樹; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022
• 当院における「いきなりエイズ」症例の患者特性の検討
  荒隆英; 荒隆英; 遠藤知之; 遠藤知之; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 高橋承吾; 高橋承吾; 横山翔大; 横山翔大; 長谷川祐太; 長谷川祐太; 松川敏大; 松川敏大; 後藤秀樹; 後藤秀樹; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022
• 薬害HIV感染症患者における冠動脈スクリーニング
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横山翔大; 高橋承吾; 高橋承吾; 須藤啓斗; 須藤啓斗; 宮島徹; 宮島徹; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022
• HIV感染者に対する骨代謝異常の後方視的解析
  松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 高橋承吾; 高橋承吾; 横山翔大; 横山翔大; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 橋野聡; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022
• 血小板輸血副作用発症に対する予防投与の有効性に関しての検討(Effectiveness of premedication in preventing reactions to platelet transfusion)
  長井 惇; 松川 敏大; 須藤 啓斗; 押味 和夫; 宮城島 拓人, 臨床血液, 59, 9, 1541, 1541, Sep. 2018
  (一社)日本血液学会-東京事務局, English
• びまん性大細胞型B細胞性リンパ腫における診断時の栄養状態と予後に関する後方視的検討(Prognostic value of nutritional status in patients with diffuse large B cell lymphoma)
  須藤 啓斗; 松川 敏大; 長井 惇; 押味 和夫; 小田 寿; 宮城島 拓人, 臨床血液, 59, 9, 1558, 1558, Sep. 2018
  (一社)日本血液学会-東京事務局, English
• MTX中止後に自然消退し、再燃を認めた古典的ホジキンリンパ腫
  須藤 啓斗; 松川 敏大; 長井 惇; 押味 和夫; 宮城島 拓人, 臨床血液, 59, 7, 969, 969, Jul. 2018
  (一社)日本血液学会-東京事務局, Japanese
• 薬剤性肝炎後に発症した肝炎後再生不良性貧血
  長井 惇; 松川 敏大; 須藤 啓斗; 押味 和夫; 宮城島 拓人, 臨床血液, 59, 7, 971, 971, Jul. 2018
  (一社)日本血液学会-東京事務局, Japanese
• 単一施設における消化管原発悪性リンパ腫の解析
  須藤 啓斗; 松川 敏大; 押味 和夫; 宮城島 拓人, 臨床血液, 58, 12, 2463, 2463, Dec. 2017
  (一社)日本血液学会-東京事務局, Japanese
• 骨格筋原発アミロイドーシスを伴った多発性骨髄腫
  松川 敏大; 江口 克紀; 須藤 啓斗; 押味 和夫; 宮城島 拓人, 臨床血液, 58, 12, 2469, 2470, Dec. 2017
  (一社)日本血液学会-東京事務局, Japanese
• 遷延性血小板減少とアルブミン、γグロブリンの低下を伴う脾原発組織球肉腫の脾摘後再発例
  須藤 啓斗; 宮城島 拓人; 松川 敏大; 押味 和夫; 高橋 達郎, 臨床血液, 58, 11, 2294, 2294, Nov. 2017
  (一社)日本血液学会-東京事務局, Japanese
• 外来でE-Ld療法を受ける多発性骨髄腫患者の内服アドヒアランス向上への取り組み
  佐々木 朋子; 小林 良充; 松川 敏大; 村山 由佳子; 松浦 理沙; 宮城島 拓人; 三浦 郁恵; 野澤 美佳; 矢澤 敏; 佐々木 祐美, 日本癌治療学会学術集会抄録集, 55回, P8, 5, Oct. 2017
  (一社)日本癌治療学会, Japanese
• 多発性骨髄腫における免疫グロブリン遊離軽鎖κ/λ比の早期正常化は無増悪生存期間を延長する
  松川 敏大; 押味 和夫; 須藤 啓斗; 宮城島 拓人, International Journal of Myeloma, 7, 1, 64, 64, Apr. 2017
  (一社)日本骨髄腫学会, Japanese
• 高齢者慢性骨髄性白血病に対するチロシンキナーゼ阻害剤治療の後方視的検討
  太田秀一; 小林一; 伊東慎市; 松川敏大; 進藤基博; 山本聡; 幸田久平; 柿木康孝; 豊嶋崇徳; 黒澤光俊, 日本臨床腫瘍学会学術集会(CD-ROM), 15th, 2017
• 造血幹細胞移植施設へ転院前に患者用パンフレットを渡すことに対する有効性の検討
  小室拓人; 松浦理沙; 松川敏大; 須藤啓斗; 鈴木梨佳子; 田口沙由里; 倉本安弥; 尾野幸子; 石黒聡美; 宮城島拓人; 佐々木祐美, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017
• 急性リンパ性白血病に対する非血縁者間同種骨髄移植後に生じた特発性大腿骨頭壊死
  松川敏大; 押味和夫; 須藤啓斗; 長井惇; 宮城島拓人, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017
• Severe Adverse Events By First Line Tyrosine Kinase Inhibitors Decrease Survival Rate in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
  Shuichi Ota; Toshihiro Matsukawa; Satoshi Yamamoto; Shinichi Ito; Motohiro Shindo; Kazuya Sato; Takeshi Kondo; Tohru Takahashi; Tsutomu Sato; Yasutaka Kakinoki; Hajime Kobayashi; Mitsutoshi Kurosawa, BLOOD, 128, 22, Dec. 2016
  English, Summary international conference
• JAK2V617F変異陰性多血症の臨床像
  松川 敏大; 押味 和夫; 千葉 雅尋; 岡田 耕平; 宮城島 拓人, 臨床血液, 57, 12, 2611, 2611, Dec. 2016
  (一社)日本血液学会-東京事務局, Japanese
• ART治療中に症候性多発性骨髄腫を発症し、寛解後にPlasmablastic plasmacytoma(or lymphoma)を口腔領域に発症して腫瘍死した一剖検例
  宮城島 拓人; 押野 智博; 更科 耕一郎; 山村 貴洋; 松田 宗一郎; 千葉 雅尋; 中野 真太郎; 松川 敏大; 小林 良充; 羽場 真; 高橋 一宏; 寺下 勝巳; 曽我部 進; 小田 寿; 藤盛 真樹; 高橋 達郎, 日本エイズ学会誌, 18, 4, 445, 445, Nov. 2016
  (一社)日本エイズ学会, Japanese
• 肺胞蛋白症を合併し致死的な経過を辿った骨髄異形成症候群の1例
  大東 寛幸; 松川 敏大; 金谷 穣; 後藤 秀樹; 橋本 大吾; 加畑 馨; 遠藤 知之; 田中 伸哉; 豊嶋 崇徳, 臨床血液, 57, 11, 2398, 2398, Nov. 2016
  (一社)日本血液学会-東京事務局, Japanese
• 無症候性の治癒切除不能進行大腸癌に対する姑息手術先行の有用性についての検討
  中野 真太郎; 小林 良充; 更科 耕一郎; 山村 貴洋; 千葉 雅博; 松田 宗一郎; 松川 敏大; 寺下 勝巳; 高橋 一宏; 羽場 真; 曽我部 進; 小田 寿; 宮城島 拓人, 日本癌治療学会学術集会抄録集, 54回, P11, 5, Oct. 2016
  (一社)日本癌治療学会, Japanese
• 当院における同種末梢血幹細胞採取の検討
  杉田 純一; 大東 寛幸; 橋口 淳一; 松川 敏大; 金谷 穣; 小杉 瑞葉; 松岡 里湖; 後藤 秀樹; 小野澤 真弘; 橋本 大吾; 加畑 馨; 藤本 勝也; 遠藤 知之; 近藤 健; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 62, 3, 490, 490, Jun. 2016
  (一社)日本輸血・細胞治療学会, Japanese
• 悪性リンパ腫への造血幹細胞移植におけるFludarabine-MelphalanレジメンとFludarabine-Busulfanレジメンの後方視的比較
  後藤秀樹; 後藤秀樹; 中澤誠多郎; 大東寛幸; 松川敏大; 金谷稔; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016
• 急性GVHD予防における短期メトトレキセート投与量の検討
  松川敏大; 杉田純一; 中澤誠多朗; 阿部貴恵; 柏崎晴彦; 大東寛幸; 金谷穣; 後藤秀樹; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 山崎裕; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016
• 初回ART導入におけるRaltegravirとDolutegravirの血液毒性への関与
  後藤秀樹; 後藤秀樹; 遠藤知之; 藤本勝也; 近藤健; 加畑馨; 橋本大吾; 小野澤真弘; 杉田純一; 松川敏大; 笠原耕平; 宮下直洋; 橋野聡; 佐藤典宏; 豊嶋崇徳, 日本エイズ学会誌, 17, 4, 510, 510, 20 Nov. 2015
  (一社)日本エイズ学会, Japanese
• Cardio-ankle vascular index(CAVI)を用いたHIV感染者の動脈硬化の評価とリスク因子の検討
  遠藤 知之; 宮下 直洋; 笠原 耕平; 渡部 恵子; 武内 阿味; 松川 敏大; 金谷 穣; 小杉 瑞葉; 松岡 里湖; 後藤 秀樹; 杉田 純一; 小野澤 真弘; 橋本 大吾; 加畑 馨; 藤本 勝也; 近藤 健; 橋野 聡; 豊嶋 崇徳, 日本エイズ学会誌, 17, 4, 392, 392, Nov. 2015
  日本エイズ学会, Japanese
• An inhibitory receptor leukocyte mono-immunoglobulin-like receptor 3/CD300f deficiency aggravates DSS-induced colitis
  Toshihiro Matsukawa; Takanori Teshima; Ko Okumura; Jiro Kitaura, JOURNAL OF IMMUNOLOGY, 194, May 2015
  English, Summary international conference
• 抑制型免疫レセプターLMIR3/CD300fの欠損はDSS腸炎を増悪させる
  松川敏大; 松川敏大; 松川敏大; 伊沢久未; 伊沢久未; 北村俊雄; 北浦次郎; 北浦次郎, 日本分子生物学会年会プログラム・要旨集(Web), 37th, 2014
• 異性間同種造血幹細胞移植後のキメリズム解析における再発とドナー由来白血病の判別
  松川 敏大; 重松 明男; 早坂 光司; 藤澤 真一; 浅沼 真介; 安本 篤史; 後藤 秀樹; 高畑 むつみ; 遠藤 知之; 田中 淳司; 橋野 聡; 今村 雅寛; 豊嶋 崇徳, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 88, 2, 93, 01 Apr. 2013
  Japanese
• 臍帯血細胞移植後にサイトメガロウイルス脳室脳炎を発症した菌状息肉症の一剖検例
  高橋健太; 松川敏大; 後藤秀樹; 遠藤知之; 橋野聡; 木村太一; 谷野美智枝; 西原広史; 田中伸哉; 田中伸哉, 日本病理学会会誌, 101, 1, 2012
• Monosomal Karyotype in Myeloid Malignancies Is Prognostically Worse Even After Allogeneic Hematopoietc Stem Cell Transplantation; Results From Two Transplant Centers
  Minauchi Koichiro; Akio Shigematsu; Masanobu Nakata; Toshihiro Matsukawa; Koh Ebata; Tomohiro Yamakawa; Tomoyuki Saga; Kanako Shima; Makoto Ibata; Junichi Sugita; Shuichi Ota; Kiyotoshi Imai; Teiichi Hirano; Masahiro Ogasawara; Yoshio Kiyama; Masahiro Imamura; Naoki Kobayashi, BLOOD, 118, 21, 1777, 1777, Nov. 2011
  English, Summary international conference
• 同種末梢血幹細胞採取に関するドナー要因の検討
  嶋香菜子; 桂有希; 松川敏大; 金谷穣; 小杉瑞葉; 松岡里湖; 野口晋佐; 藤井志朗; 太田秀一; 中田匡信; 今井陽俊; 平野貞一; 小林直樹; 小笠原正浩; 木山善雄; 笠井正晴, 日本アフェレシス学会雑誌, 29, 1, 2010
• 細胞表面抗原を用いた制御性T細胞の分離・増殖
  小笠原正浩; 松川敏大; 桂有希; 嶋香菜子; 金谷穣; 小杉瑞葉; 松岡里湖; 藤井志朗; 野口晋佐; 太田秀一; 中田匡信; 今井陽俊; 平野貞一; 小林直樹; 木山善雄; 笠井正晴, 臨床血液, 50, 9, 2009
• 慢性骨髄性白血病におけるイマチニブ血中濃度と有効性についての検討
  藤井志朗; 今井陽俊; 松川敏大; 桂有希; 嶋香菜子; 金谷穣; 小杉瑞葉; 松岡里湖; 野口晋佐; 太田秀一; 中田匡信; 平野貞一; 小林直樹; 小笠原正浩; 木山喜雄; 笠井正晴, 臨床血液, 50, 9, 2009
• クラインフェルター症候群に合併した急性前骨髄球性白血病
  松川 敏大; 白尾 さや香; 酒井 俊郎; 小沼 祐一; 黒田 裕行; 幸田 久平, 旭川赤十字病院医学雑誌, 21, 33, 37, Aug. 2008
  肉眼的血尿を主訴とし、尿潜血、尿蛋白異常、白血球高値、血小板低値、血圧上昇を指摘された46歳男性症例について検討した。播種性血管内凝固症候群(DIC)スコアは、白血病、および類縁疾患に関する診断基準で5点であった。また、初診時、知能は正常、外観は正常男性であったが、精巣容積は約7.5mlであった。骨髄検査では、有核細胞数は8万で、うちblast 9.4%、promyelocyte 78.6%、アズール顆粒が豊富でアウエル小体やファゴットを有する細胞が高率に発現していた。核型分析では47、XXYが20/20細胞に、t(15;17)が18/20細胞にみられた。骨髄血細胞表面マーカーはCD13・CD33陽性、HLA-DR陰性であった。入院時に行ったRML-RARαはFISH法で99.0%であった。クラインフェルター症候群(KS)とDICを伴ったFAB分類の急性前骨髄球性白血病(AML M3)と診断した。寛解導入療法、およびDICに対する治療の後、地固め療法を行ったところ、分子的完全寛解が得られた。造血器腫瘍合併のKSを診断した際の注意点としては、他の悪性腫瘍を高率に合併すること、治療後の二次癌発生に注意を払う必要が有ると考えられた。, 旭川赤十字病院編集委員会, Japanese

• 日本性感染症学会
• 日本エイズ学会
• 日本輸血・細胞療法学会
• 日本造血・免疫細胞療法学会
• 日本血液学会
• 日本内科学会

• NUP98::NSD1白血病の治療抵抗性の解明と新規治療法の開発
  科学研究費助成事業
  01 Apr. 2023 - 31 Mar. 2026
  松川 敏大; 平林 真介; 小野澤 真弘
  北海道白血病ネットのヒト臨床検体からNUP98::NSD1をクローニングした。NUP98::NSD1全長が非常に長いため、全長をそのままクローニングを行うことは困難であった。まず、全長を前半部分と後半部分に分けてクローニングを行い、前半・後半部分をそれぞれPCRで増幅しベクターを制限酵素で切断した。切断部分にNUP98::NSD1の前半・後半部分を挿入し、形質転換後にプラスミド抽出を行った。それぞれの配列をサンガーシークエンスで確認すると一部に塩基置換が認められ、PCR法などによる修復を行ない、シークエンスを復元することができた。前半部分と後半部分を結合させ、全長をサンガーシークエンスで確認し、変異のないことを確認した。
  当初、出来上がったNUP98::NSD1をB細胞系細胞株であるBa/F3に遺伝子導入したのちに薬剤選択により細胞株を樹立した。しかし、樹立したと思われる細胞株においてNUP98::NSD1の融合蛋白を確認できなかった。同様の手法で、他のヒト細胞株にも遺伝子導入を行ったが、同様に融合蛋白を認めることが困難であった。
  薬剤耐性株は樹立できているが目的とする蛋白の発現が見られない。
  この原因については判然とはしていないが、目的とする蛋白の発現が見られない以上は薬剤耐性にはなっているが何らかの原因で融合蛋白が作成できていないと考えた。
  現在は、別のベクターに乗せ替えを行ってから、再度遺伝子導入を行い、今後NUP98::NSD1陽性ヒト細胞株の樹立を目指すことを目標としている。
  日本学術振興会, 基盤研究(C), 北海道大学, 23K07802
• Unveiling NUP98-NSD1 leukemia
  Grants-in-Aid for Scientific Research
  31 Aug. 2022 - 31 Mar. 2024
  Matsukawa Toshihiro
  This study identified NUP98-NSD1-positive acute myeloid leukemia from specimens which collected by the Hokkaido Leukemia Net. We next cloned NUP98-NSD1 and confirmed the full length of the vector by Sanger sequencing.
  Then we transfected NUP98-NSD1 into Ba/F3, the human B-cell line, and selected it by puromycin. However, because the expression of the NUP98-NSD1 fusion protein could not be detected by immunoblotting, we tried to transduce other human cell lines.
  Japan Society for the Promotion of Science, Grant-in-Aid for Research Activity Start-up, Hokkaido University, 22K20842
• 白血病やＧＶＨＤにおける新規のペア型免疫レセプターを標的とした治療法の開発
  科学研究費助成事業
  25 Apr. 2014 - 31 Mar. 2016
  松川 敏大
  前年度までの研究成果として腸管に存在するマスト細胞表面のATP受容体であるP2X7受容体からの刺激をペア型免疫抑制レセプターであるLMIR3/CD300fが制御しており、その結果LMIR3/CD300fは炎症性腸疾患の制御をおこなっていることについて報告を行った。その結果から本年度は腸管粘膜の炎症として共通する腸管GVHDとLMIR3/CD300fとの関連について検討を行った。炎症性腸疾患ではLMIR3/CD300fは欠損により増悪し、一方、GVHDではその欠損により病態が軽減する。このことから何らかの因子が影響すると思われるが、LMIR3/CD300f欠損マスト細胞欠損マウスにLMIR3/CD300fを強制発現させたマスト細胞を再構築すると野生型のマウスのGVHDと同様の結果になるが、一方で、LMIR3/CD300f欠損マスト細胞欠損マウスにLMIR3/CD300f欠損のマスト細胞を再構築しても、LMIR3/CD300f欠損マウスにGVHDを引き起こした際と同様の病態には至らなかった。したがって、GVHDにおいてはマスト細胞表面に存在するLMIR3/CD300fだけが病態に影響を及ぼしているわけではなく、その他の因子（例えば、リンパ球表面に存在するLMIR3/CD300f）が関与する可能性が示唆された。しかし、その因子の追求については現在までのところ、同定には至っていない状況である。また、LMIR3/CD300fと白血病についての検討は今後ヒト検体を用いた解析を施行したいと考えているが、現在までのところ公表できるデータは乏しい。
  日本学術振興会, 特別研究員奨励費, 北海道大学, 14J00014